Estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (Her2) represent the elements that define these breast cancer subtypes and are routinely obtained to guide systemic therapy decision making. This evidence concerns the gene PGR and breast cancer.